Pharming Group N.V. announced that its Extraordinary General Meeting of Shareholders adopted all proposals on the agenda, including the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer.
Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect, taking on the leadership role for a term of four years. Mr. de Vries will remain a strategic advisor to the new CEO until December 31, 2025, to ensure a smooth transition.
The Board of Directors welcomed Mr. Chouraqui, expressing anticipation for his leadership in delivering on Pharming’s objectives and strengthening its position in the rare disease market. Shareholders also approved components of Mr. Chouraqui's remuneration package.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.